Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms

2022131 citationsJournal Articlebronze Open Access

Authors

Keith S. Kaye · Rutgers, The State University of New Jersey

Dror Marchaim · Assaf Harofeh Medical Center

Visanu Thamlikitkul · Siriraj Hospital

Yehuda Carmeli · Tel Aviv University

Cheng‐Hsun Chiu · Chang Gung Memorial Hospital

George L. Daikos · National and Kapodistrian University of Athens

Sorabh Dhar

Abstract

Combination therapy with colistin and meropenem was not superior to colistin monotherapy for the treatment of pneumonia or BSI caused by these pathogens. (Funded by the National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases protocol 10-0065; ClinicalTrials.gov number, NCT01597973.).

Topics & Keywords

Antibiotic Resistance in Bacteria Pneumonia and Respiratory Infections Antibiotics Pharmacokinetics and Efficacy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: NEJM Evidence

Volume 2, Issue 1

DOI: 10.1056/evidoa2200131

Field-Weighted Citation Impact: 8.73